ArticleScientific reports2016
Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.Journal of hematology & oncology · 2016Trial
- Stage-specific disruption of erythropoiesis leads to anemia in newly diagnosed multiple myeloma patients.Frontiers in cell and developmental biology · 2026Article
- Analysis of Bone Histomorphometry in Rat and Guinea Pig Animal Models Subject to Hypoxia.International journal of molecular sciences · 2022Article
- Molecular Mechanisms Involved in Hypoxia-Induced Alterations in Bone Remodeling.International journal of molecular sciences · 2022Review
- Animal Models of Multiple Myeloma Bone Disease.Frontiers in genetics · 2021Review
- Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment.Scientific reports · 2020Article
- Erythropoietin and its derivatives: from tissue protection to immune regulation.Cell death & disease · 2020Review
- Erythropoietin receptor in B cells plays a role in bone remodeling in mice.Theranostics · 2020Article
- Erythropoiesis, EPO, macrophages, and bone.Bone · 2019Review
- Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway.Haematologica · 2018Article
- Erythropoietin enhances Kupffer cell number and activity in the challenged liver.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a plasma cell malignancy, characterized by osteolytic lesions and monoclonal immunoglobulins. The anemia, accompanying the disease is often treated with recombinant human EPO. Diverse non-erythropoietic effects of EPO have led us to question its combined action on the immune system and bone in the 5T33MM mouse model. EPO administration to MM mice attenuated disease progression as demonstrated by a decrease in serum MM IgG2b, splenic CD138 expressing cells, IL-6 and RORγτ transcripts in bone marrow (BM). IFN-γ transcript levels and macrophages (F4/80(+)CD11b(+)) in the BM both increased ~1.5 fold in the EPO-treated MM mice. In-vitro, EPO stimulated phagocytosis of 5T33MM cells (+30%) by BM-derived macrophages. In contrast, high-resolution microCT analysis of distal femurs revealed EPO-associated bone loss in both healthy and 5T33MM mice. EPO significantly increased expression of the osteoclastogenic nuclear factor-kappa B ligand (RANKL) in healthy mice, but not in MM mice, likely due to antagonizing effects on MM progression. Thus, in MM, EPO may act as a double-edged-sword stimulating immune response, while accelerating bone resorption, possibly via direct action on BM macrophages. This study supports a prudent approach of treating anemia in MM patients, aiming to maintain EPO-associated anti-MM effects, while considering bone damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.